Introducing Dx:Revenue - Precision Medicine Intelligence for Business Development Teams

LEARN MORE
Posts From the monthly archives: "April 2013"

More from Bruce Booth with a realistic (and pessimistic) perspective on diagnostic investments and related challenges. Key question: “…how does one generate a return from early stage diagnostic investing – the translation of academia-derived insights into new clinically-validated diagnostic tests. Who is going to fund the next generation of new innovative Dx plays?” Unhealthy…(Read More)

On-Q-ity, a Cancer Diagnostic Company: R.I.P. | LifeSciVC. Lots of lessons from this story, but two of the key ones are: 1. Clinical trials are costly and risky. The company’s first investments were in 4 clinical trials for their most promising biomarkers, all of which failed. This effort consumed the better…(Read More)

Interesting opinion piece rebutting an open letter from Peter Meldrum, CEO of Myriad, in advance of the Supreme Court’s decision on the patentability of BRCA1/BRCA2. Myriad Genetics CEO Claims He Owns Your Genes – Forbes. Patents support the public good when the investments required to bring an advancement into the market are high enough…(Read More)